Evidence map›Paper›PMID 38504106›Full record

ArticleCommunications medicine2024

Early elevated IFNα is a key mediator of HIV pathogenesis.

Hélène Le Buanec, Valérie Schiavon, Marine Merandet, Alexandre How-Kit, David Bergerat, Céline Fombellida-Lopez, Armand Bensussan, Jean-David Bouaziz, Arsène Burny, Gilles Darcis and 5 more

Open access · goldAbstract read
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. IFNα induces CCR5 in CD4Communications medicine · 2024
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 4 countries.

Hélène Le BuanecUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.
Valérie SchiavonUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.
Marine MerandetUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.
Alexandre How-KitLaboratory for Genomics Foundation Jean Dausset-CEPH, Paris, France.
David BergeratUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.ORCID http://orcid.org/0000-0003-0013-6621
Céline Fombellida-LopezLaboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium.
Armand BensussanUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.ORCID http://orcid.org/0000-0002-0409-2497
Jean-David BouazizUniversité de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010, Paris, France.
Arsène BurnyLaboratory of Molecular Biology, Gembloux Agrobiotech, University of Liège, Liège, Belgium.
Gilles DarcisLaboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege, 4000, Liege, Belgium.
Hongshuo SongInstitute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Mohammad M SajadiGlobal Virus Network, Baltimore, MD, 21201, USA.
Shyamasundaran KottililGlobal Virus Network, Baltimore, MD, 21201, USA.
Robert C GalloGlobal Virus Network, Baltimore, MD, 21201, USA. rgallo@ihv.umaryland.edu.ORCID http://orcid.org/0000-0002-3797-7910
Daniel Zagury21CBIO, Paris, France.
Inserm · FRUniversity of Maryland, Baltimore · USUniversity of Liège · BEFondation Jean Dausset-CEPH · FR

Funding

Engineering of pan-neutralizing anti-HIV envelope antibodiesR01AI147870 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2020 to 2024
$2.5M
Discovery of acidic epitopes for HIV-1 broadly neutralizing seroantibodiesI01BX002358 · VA · BALTIMORE VA MEDICAL CENTER · PI SAJADI, MOHAMMAD MOHSENI · 2015 to 2019
–
BLRD VA I01 BX002358BLRD VA I01 BX004525NIAID NIH HHS R01 AI147870
6 · The paper itself

Abstract

backgroundA complete understanding of the different steps of HIV replication and an effective drug combination have led to modern antiretroviral regimens that block HIV replication for decades, but these therapies are not curative and must be taken for life. "Elite controllers" (ECs) is a term for the 0.5% of HIV-infected persons requiring no antiretroviral therapy, whose status may point the way toward a functional HIV cure. Defining the mechanisms of this control may be key to understanding how to replicate this functional cure in others.

methodsIn ECs and untreated non-EC patients, we compared IFNα serum concentration, distribution of immune cell subsets, and frequency of cell markers associated with immune dysfunction. We also investigated the effect of an elevated dose of IFNα on distinct subsets within dendritic cells, natural killer cells, and CD4+ and CD8 + T cells.

resultsSerum IFNα was undetectable in ECs, but all immune cell subsets from untreated non-EC patients were structurally and functionally impaired. We also show that the altered phenotype and function of these cell subsets in non-EC patients can be recapitulated when cells are stimulated in vitro with high-dose IFNα.

conclusionsElevated IFNα is a key mediator of HIV pathogenesis.

Identifiers

PMID38504106
PMCPMC10951235
OpenAlexW4392939204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.